Personalized Regenerative Medicine
Personalized medicine as a novel field of medicine refers to the prescription of specific therapeutics procedure for an individual. This approach has established based on pharmacogenetic and pharmacogenomic information and data. The terms precision and personalized medicines are sometimes applied interchangeably. However, there has been a shift from “personalized medicine” towards “precision medicine”. Although personalized medicine emerged from pharmacogenetics, nowadays it covers many fields of healthcare. Accordingly, regenerative medicine and cellular therapy as the new fields of medicine use cell-based products in order to develop personalized treatments. Different sources of stem cells including mesenchymal stem cells, embryonic stem cells and induced pluripotent stem cells (iPSCs) have been considered in targeted therapies which could give many advantages. iPSCs as the novel and individual pluripotent stem cells have been introduced as the appropriate candidates for personalized cell therapies. Cellular therapies can provide a personalized approach. Because of person-to-person and population differences in the result of stem cell therapy, individualized cellular therapy must be adjusted according to the patient specific profile, in order to achieve best therapeutic results and outcomes. Several factors should be considered to achieve personalized stem cells therapy such as, recipient factors, donor factors, and the overall body environment in which the stem cells could be active and functional. In addition to these factors, the source of stem cells must be carefully chosen based on functional and physical criteria that lead to optimal outcomes.
Jain K. Personalized medicine. Curr Opin Mole Ther 2002;4:548-58.
Jain KK, editor. Textbook of personalized medicine. 1st ed. New York: Springer, 2009:165-295.
Debnath M, Prasad GB, Bisen PS, eds. Molecular diagnostics: promises and possibilities. 4th ed. Dordrecht: Springer Netherlands, 2010:393-410.
McCabe C, Husereau D. Personalized Medicine and Health Care Policy: From Science to Value. (Accessed Feb. 02, 2017, at https://www.genomecanada.ca/.../ PersonalizedMedecine_Policy-Directions-Brief).
Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med 2015;372:793-5.
Pavlović S, Zukić B, Stojiljković Petrović M. Molecular Genetic Markers as a Basis for Personalized Medicine. J Med Biochem 2014;33:8-21.
Zhang XD. Optimal high-throughput screening: practical experimental design and data analysis for genome-scale RNAi research, Cambridge Univ Press,2011:3-106
Katsnelson A. Momentum grows to make'personalized'medicine more 'precise'. Nat Med 2013;19:249.
Jameson JL, Longo DL. Precision medicine—personalized, problematic, and promising. N Engl J Med
Disease NRCCoAFfDaNTo. Toward precision medicine: building a knowledge network for biomedical research and a new taxonomy of disease: National Academies Press (US), 2011.
Zhang X. Precision Medicine. Personalized Medicine, Omics and Big Data: Concepts and Relationships. J Pharmacogenomics Pharmacoproteomics 2015;6:e144.
Janowski M, Bulte JW, Walczak P. Personalized nanomedicine advancements for stem cell tracking. Adv Drug Deliv Rev 2012;64:1488-507.
Bates S. Progress towards personalized medicine. Drug Discov Today 2010;15:115-20.
Becher UM, Tiyerili V, Skowasch D, Nickenig G, Werner N. Personalized cardiac regeneration by stem cells–Hype or hope? EPMA J 2011;2:119-30.
Lu YF, Goldstein DB, Angrist M, Cavalleri G.Personalized medicine and human genetic diversity. Cold Spring Harb Perspect Med 2014;4:a008581.
Nelson TJ, Behfar A, Terzic A. Strategies for therapeutic repair: The "R(3)" regenerative medicine paradigm. Clin Transl Sci 2008;1:168-71.
Atala A. Regenerative medicine strategies. J Pediatr surg 2012;47:17-28.
Buckler RL. Opportunities in regenerative medicine.BioProcess Int 2011;9:1419.
Harris DT. Stem cell banking for regenerative and personalized medicine. Biomedicines 2014;2:50-79.
Hipp J, Atala A. Sources of stem cells for regenerative medicine. Stem Cell Rev 2008;4:3-11.
Mahla RS. Stem Cells Applications in Regenerative Medicine and Disease Therapeutics. Int J Cell Biol
Sakurada K, McDonald FM, Shimada RF. Regenerative medicine and stem cell based drug discovery. Angew Chem Int Ed 2008;47:5718-38.
Mao AS, Mooney DJ. Regenerative medicine: Current therapies and future directions. Proc Natl Acad Sci
Fisher MB, Mauck RL. Tissue engineering and regenerative medicine: recent innovations and the transition to translation. Tissue Eng Part B Rev
Arbab AS, Janic B, Haller J, Pawelczyk E, Liu W, Frank JA. In vivo cellular imaging for translational medical research. Curr Med Imaging Rev 2009;5:19-38.
Schroeder IS. Stem cells: are we ready for therapy?Methods Mol Biol 2014;1453-51.
Buzhor E, Leshansky L, Blumenthal J, Barash H, Warshawsky D, Mazor Y, et al. Cell-based therapy approaches: the hope for incurable diseases. Regen Med 2014;9:649-672.
Goodarzi P, Aghayan HR, Soleimani M, Norouzi- Javidan A, Mohamadi-Jahani F, Jahangiri S, et al. Stem cell therapy for treatment of epilepsy. Acta Med Iran 2014;52:651-5.
Goodarzi P, Aghayan HR, Larijani B, Soleimani M, Dehpour AR, Sahebjam M, et al. Stem cell-based approach for the treatment of Parkinson's disease. Med J Islam Repub Iran 2015;29:168.
Chang KA, Lee JH, Suh YH. Therapeutic potential of human adipose-derived stem cells in neurological disorders. J Pharmacol Sci 2014;126:293-301.
Soleimani M, Aghayan HR, Goodarzi P, Farshdousti M, Ardeshiry Lajimi A, Saki N, et al. Stem Cell Therapy Approach for Multiple Sclerosis Treatment. Arch Neurosci 2016;3:e21564
Daley GQ, Scadden DT. Prospects for stem cell-based therapy. Cell 2008;132:544-8.
Kolios G, Moodley Y. Introduction to stem cells and regenerative medicine. Respiration 2013;85:3-10.
Rodrigues MCO, Glover LE, Weinbren N, Rizzi JA, Ishikawa H, Shinozuka K, et al. Toward personalized cell therapies: autologous menstrual blood cells for stroke. Biomed Res Int 2011;2011.
Patel SA, King CC, Lim PK, Habiba U, Dave M, Porecha R, et al. Personalizing stem cell research and therapy: the arduous road ahead or missed opportunity? Curr Pharmacogenomics Person Med 2010;8:25-36.
Rodrigues MC, Glover LE, Weinbren N, Rizzi JA,Ishikawa H, Shinozuka K, et al. Toward personalized cell therapies: autologous menstrual blood cells for stroke. J Biomed Biotechnol 2011;2011:194720.
Prasongchean W, Ferretti P. Autologous stem cells for personalised medicine. N Biotechnol 2012;29:641-50.
Gimble JM, Katz AJ, Bunnell BA. Adipose-derived stem cells for regenerative medicine. Circ Res 2007;100:1249-60.
Aghayan HR, Goodarzi P, Arjmand B. GMP-compliant human adipose tissue-derived mesenchymal stem cells for cellular therapy. Methods Mol Biol 2015;1283:93-107.
Larijani B, Aghayan H, Goodarzi P, Mohamadi-Jahani F, Norouzi-Javidan A, Dehpour AR, et al. Clinical Grade Human Adipose Tissue-Derived Mesenchymal Stem Cell Banking. Acta Med Iran 2015;53:540-6.
Drukker M, Benvenisty N. The immunogenicity of human embryonic stem-derived cells. Trends Biotechnol 2004;22:136-41.
Leist M, Bremer S, Brundin P, Hescheler J, Kirkeby A, Krause KH, et al. The biological and ethical basis of the use of human embryonic stem cells for in vitro test systems or cell therapy. ALTEX 2008;25:163-90.
Müller R, Lengerke C. Patient-specific pluripotent stem cells: promises and challenges. Nat Rev Endocrinol 2009;5:195-203.
Chen IY, Matsa E, Wu JC. Induced pluripotent stem cells: at the heart of cardiovascular precision medicine. Nat Rev Cardiol 2016;13:333-49.
Shtrichman RI. Germanguz, Itskovitz-Eldor J. Induced pluripotent stem cells (iPSCs) derived from different cell sources and their potential for regenerative and personalized medicine. Curr Mol Med 2013;13:792-805.
Yamanaka S. A fresh look at iPS cells. Cell2009;137:13-7.
Isobe K, Cheung HS, Wu J. Toward Personalized Cell Therapies by Using Stem Cells 2013. Biomed Res Int 2013;2013;534047.
Ebben JD, Zorniak M, Clark PA, Kuo JS. Introduction to induced pluripotent stem cells: advancing the potential for personalized medicine. World Neurosurg 2011;76:270-5.
Young W, D'Souza SL, Lemischka IR, Christoph S.Patient-specific induced pluripotent stem cells as a platform for disease modeling, drug discovery and precision personalized medicine. J Stem Cell Res Ther 2012:S10.
Snyderman R. Personalized medicine 2014: has healthcare been transformed? Per Med 2014;11:365-8.
Ely S. Personalized medicine: individualized care of cancer patients. Transl Res 2009;154:303-8.
Kim PG, Daley GQ. Application of induced pluripotent stem cells to hematologic disease. Cytotherapy 2009;11:980-9.
McNearney TA, Hunnicutt SE, Fischbach M, Friedman AW, Aguilar M, Ahn CW, et al. Perceived functioning has ethnic-specific associations in systemic sclerosis: another dimension of personalized medicine. J Rheumat 2009;36:2724-32.
Copyright (c) 2017 Acta Medica Iranica
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.